Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MicroGeneSys
Meriden, Connecticut, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
MicroGeneSys was a pioneering biopharmaceutical company known for developing VaxSyn, the first HIV/AIDS vaccine candidate to enter human clinical trials in the United States in 1987. The company was a leader in using the Baculovirus Expression Vector System (BEVS) to produce recombinant proteins. Despite early promise and significant political visibility, the company's vaccine candidates failed to show sufficient efficacy in Phase 2 trials, and the company eventually ceased operations in the mid-1990s following financial and legal difficulties.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineRecombinant protein
- Industry
- Biotech
02
Partnerships
National Institute of Allergy and Infectious Diseases (NIAID)Walter Reed Army Institute of Research
Beyond the preview
Go deeper on MicroGeneSys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroGeneSys.